BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

522 related articles for article (PubMed ID: 16179880)

  • 1. New drug-eluting stents, optimizing technique, and the problem of drug-eluting stent restenosis.
    Vaina S; Ong AT; Serruys PW
    Minerva Cardioangiol; 2005 Oct; 53(5):341-60. PubMed ID: 16179880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-eluting stents.
    García-García HM; Vaina S; Tsuchida K; Serruys PW
    Arch Cardiol Mex; 2006; 76(3):297-319. PubMed ID: 17091802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-eluting stent: the emerging technique for the prevention of restenosis.
    Sheiban I; Carrieri L; Catuzzo B; Destefanis P; Oliaro E; Moretti C; Trevi GP
    Minerva Cardioangiol; 2002 Oct; 50(5):443-53. PubMed ID: 12384626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-eluting coronary stents: many meta-analyses, little benefit.
    Prescrire Int; 2009 Apr; 18(100):70-4. PubMed ID: 19585727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-eluting stents: results, promises and problems.
    van der Hoeven BL; Pires NM; Warda HM; Oemrawsingh PV; van Vlijmen BJ; Quax PH; Schalij MJ; van der Wall EE; Jukema JW
    Int J Cardiol; 2005 Mar; 99(1):9-17. PubMed ID: 15721493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are impaired endothelial progenitor cells involved in the processes of late in-stent thrombosis and re-endothelialization of drug-eluting stents?
    Zhao FH; Chen YD; Jin ZN; Lu SZ
    Med Hypotheses; 2008; 70(3):512-4. PubMed ID: 17764856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of sirolimus versus paclitaxel eluting stents for treatment of coronary in-stent restenosis.
    Airoldi F; Briguori C; Iakovou I; Stankovic G; Biondi-Zoccai G; Carlino M; Chieffo A; Montorfano M; Cosgrave J; Michev I; Rogacka R; Sangiorgi GM; Colombo A
    Am J Cardiol; 2006 Apr; 97(8):1182-7. PubMed ID: 16616023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term clinical outcomes after sirolimus-eluting stent implantation for treatment of restenosis within bare-metal versus drug-eluting stents.
    Whan Lee C; Kim SH; Suh J; Park DW; Lee SH; Kim YH; Hong MK; Kim JJ; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2008 Apr; 71(5):594-8. PubMed ID: 18311841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current status and future prospects of drug eluting stents for restenosis.
    Patel MJ; Patel SS; Patel NS; Patel NM
    Acta Pharm; 2012 Dec; 62(4):473-96. PubMed ID: 23333885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-stent restenosis.
    Kim MS; Dean LS
    Cardiovasc Ther; 2011 Jun; 29(3):190-8. PubMed ID: 20406239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents.
    Caixeta A; Leon MB; Lansky AJ; Nikolsky E; Aoki J; Moses JW; Schofer J; Morice MC; Schampaert E; Kirtane AJ; Popma JJ; Parise H; Fahy M; Mehran R
    J Am Coll Cardiol; 2009 Sep; 54(10):894-902. PubMed ID: 19712798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zotarolimus (ABT-578) eluting stents.
    Burke SE; Kuntz RE; Schwartz LB
    Adv Drug Deliv Rev; 2006 Jun; 58(3):437-46. PubMed ID: 16581153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Late stent thrombosis with drug eluting stents: disturbing signals on the radar].
    Hansen PR
    Ugeskr Laeger; 2007 Apr; 169(17):1561-3. PubMed ID: 17484825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The paclitaxel-eluting stent in percutaneous coronary intervention: Part II. Comparison with the sirolimus-eluting stent, economics, and unanswered questions.
    Ray GM; Nawarskas JJ; Frishman WH
    Cardiol Rev; 2006; 14(3):143-50. PubMed ID: 16628023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Indications of drug eluting stents].
    Cattan S; Michaud P; Nallet O; Allouch P; Elmamoud R; Leyer F; Osman R
    Ann Cardiol Angeiol (Paris); 2004 Nov; 53(6):335-8. PubMed ID: 15603176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early experiences and clinical implications of restenosis and drug-eluting stents: Part 2.
    Chong PH; Cheng JW
    Ann Pharmacother; 2004 May; 38(5):845-52. PubMed ID: 15039482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-eluting stent for the treatment of small coronary lesion: comparison between sirolimus- and paclitaxel-eluting stent.
    Li JJ; Xu B; Yang YJ; Chen JL; Qiao SB; Ma WH; Qin XW; Yao M; Liu HB; Wu YJ; Yuan JQ; Chen J; You SJ; Dai J; Xia R; Gao RL
    Chin Med J (Engl); 2007 Apr; 120(7):569-73. PubMed ID: 17442204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized comparison of sirolimus-eluting stent implantation with zotarolimus-eluting stent implantation for the treatment of total coronary occlusions: rationale and design of the PRImary Stenting of Occluded Native coronary arteries III (PRISON III) study.
    Suttorp MJ; Laarman GJ;
    Am Heart J; 2007 Sep; 154(3):432-5. PubMed ID: 17719285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence and predictors of recurrent restenosis following implantation of drug-eluting stents for in-stent restenosis.
    Lee CW; Park CB; Kim YH; Hong MK; Kim JJ; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2007 Jan; 69(1):104-8. PubMed ID: 17139669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-eluting stents.
    Chieffo A; Colombo A
    Minerva Cardioangiol; 2002 Oct; 50(5):419-29. PubMed ID: 12384624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.